NEUROONE MEDICAL TECHNOLOGIE (NMTC)
US64130M2098 - Common Stock
NMTC gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 192 industry peers in the Health Care Equipment & Supplies industry. While NMTC seems to be doing ok healthwise, there are quite some concerns on its profitability. NMTC is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year NMTC has reported negative net income.
In the past year NMTC has reported a negative cash flow from operations.
In the past 5 years NMTC always reported negative net income.
In the past 5 years NMTC always reported negative operating cash flow.
1.2 Ratios
NMTC's Return On Assets of -231.35% is on the low side compared to the rest of the industry. NMTC is outperformed by 94.79% of its industry peers.
NMTC's Return On Equity of -304.88% is on the low side compared to the rest of the industry. NMTC is outperformed by 84.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -231.35% | ||
| ROE | -304.88% | ||
| ROIC | N/A |
ROA(3y)-116.59%
ROA(5y)-383.12%
ROE(3y)-148.61%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a Gross Margin value of 26.95%, NMTC is not doing good in the industry: 75.52% of the companies in the same industry are doing better.
The Profit Margin and Operating Margin are not available for NMTC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 26.95% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
NMTC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NMTC has been increased compared to 1 year ago.
NMTC has more shares outstanding than it did 5 years ago.
NMTC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -9.90, we must say that NMTC is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of NMTC (-9.90) is worse than 80.21% of its industry peers.
NMTC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -9.9 |
ROIC/WACCN/A
WACC10.02%
2.3 Liquidity
NMTC has a Current Ratio of 3.68. This indicates that NMTC is financially healthy and has no problem in meeting its short term obligations.
NMTC has a Current ratio (3.68) which is comparable to the rest of the industry.
A Quick Ratio of 2.52 indicates that NMTC has no problem at all paying its short term obligations.
NMTC has a Quick ratio of 2.52. This is comparable to the rest of the industry: NMTC outperforms 52.08% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.68 | ||
| Quick Ratio | 2.52 |
3. Growth
3.1 Past
The earnings per share for NMTC have decreased strongly by -21.43% in the last year.
NMTC shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -21.64%.
NMTC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.34% yearly.
EPS 1Y (TTM)-21.43%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-27.27%
Revenue 1Y (TTM)-21.64%
Revenue growth 3Y21.34%
Revenue growth 5YN/A
Revenue growth Q2Q-37.73%
3.2 Future
Based on estimates for the next years, NMTC will show a very strong growth in Earnings Per Share. The EPS will grow by 24.92% on average per year.
NMTC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 91.95% yearly.
EPS Next Y34.09%
EPS Next 2Y24.92%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year93.92%
Revenue Next 2Y91.95%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for NMTC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NMTC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as NMTC's earnings are expected to grow with 24.92% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.92%
EPS Next 3YN/A
5. Dividend
5.1 Amount
NMTC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NEUROONE MEDICAL TECHNOLOGIE
NASDAQ:NMTC (4/30/2024, 3:30:01 PM)
1.13
+0.01 (+0.89%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap29.30M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -231.35% | ||
| ROE | -304.88% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 26.95% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.68 | ||
| Quick Ratio | 2.52 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-21.43%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y34.09%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-21.64%
Revenue growth 3Y21.34%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y